Founder-CEO Interview Series

/

Erik van den Berg

Erik serves as CEO of Memo Therapeutics AG and previously was CEO at AM-Pharma from 2011 through 2023. He is Chairman of Step Pharma  and TargED Biopharmaceuticals and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead Pharma and the Dutch biotechnology organization.

As Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis (SWX/Euronext: ISON – sold to Integra Lifesciences), and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, including a $600M alliance with Pfizer, $290M partnership with Kyowa Kirin and raised ~€500M in equity and debt financing for biotechnology companies from seed through IPO.

Founder-CEO Interview Series

with Erik van den Berg

Could you tell us more about yourself?

I enjoy working with dedicated teams of highly skilled professionals to develop innovative products whilst achieving ambitious goals. You could say I am very result-oriented and a team player.

Privately, I love playing sports and enjoy good food and company. Professionally, I am and have been involved in creating and growing high-technology companies where I have led several large deals and financing rounds from seed financing through IPO.

Congratulations on your recent appointment as CEO at Memo Therapeutics AG (‘MTx’). What is the team building?

The MTx team has been very open and welcoming as well as receptive to my initial outsider perspective. After establishing a joint focus on value creation and quality we defined our short- and medium-term goals. Now we are expanding the team to support our near-term ambitions and continue to build a high-quality team at Memo Therapeutics AG.

What are the next milestones for the company?

We want to successfully conclude our ongoing Phase 2 study with our antibody against BK virus (Trapovitug) in kidney transplantation by the first half of 2025 and advance our discovery programs to substantial value inflection points by then.

You’ve been involved in the field of research for kidney-related diseases for more than a decade. What are the main challenges faced here?

The kidney is a versatile and complex organ, responsible for vital body functions. The challenge with kidney diseases has been unravelling complex disorders to find suitable targets as well as agreeing on obtainable pivotal endpoints for market authorisation.

Kidney diseases can progress slowly (but steadily) over a prolonged period, ultimately resulting in end-stage-renal disease and transplantation. Early endpoints are required to support approval, such as reducing kidney function decline measured by estimated glomerular filtration rate (eGFR) and proteinuria.

You are also the Chairman of various biotech companies. What is the main role that you play and how do you stay focused and prioritise?

I am currently Chairman of Step Pharma and TargED Therapeutics, two companies with exciting programs with a clear mode of action. Step Pharma in CTPS1 dependent cancer and TargED advancing the next generation thrombolytic.

I help management teams and boards focus on the main strategic challenges and risks to maximize the chance for the team to be successful whilst advising on key investments in product development to create value. When appropriate I leverage my network in pharma and investors to support the companies’ financing and partnering efforts.

How did your time in Pharma and consulting develop your mindset and skillset?

Starting as a strategy consultant allowed me to experience a variety of business challenges across different industries, including chemical, pharmaceutical and biotech industries. It also further shaped my analytical focus and result-oriented drive, allowing me to quickly get to the essence of the subject at hand.

Working in pharma brought in new perspectives on therapeutics development as well as important quality and manufacturing considerations. In business development you ‘re-live’ multiple development programs of potential collaborators, which broadens the experience base. Starting a family and raising children to adulthood has helped develop my patience and self-reflection.

What is one interesting fact about yourself that few people know of (a hobby, etc.)? 

I start to whistle when I am irritated and sing when I am joyful…

Insights

Related articles

Margrit Schwarz

Who inspired you to get into the life sciences? My interest for life science was nurtured by my father, who was both a chemist and a photographer; he took me along on hikes and then to the lab where I spent hours staring through a microscope, examining the things I had just picked up on the trail. It instilled in me a deep fascination for all things ‘Nature’, from patterns of life that repeat regardless of scale, to endless curiosity for – simply put – why things are the way they are!

Read More

Stephan Christgau

You have an extensive background in both academia and the biotech industry, with over 60 peer-reviewed papers and multiple patents. How has your experience as a researcher shaped your approach as a life sciences investor and entrepreneur?

I think it gives a different perspective as an investor, when you have actually had operational experience. Having started companies and worked with f.ex. patent strategy, development plans and CRO selection and monitoring is not only something I hear about in the board room, but something I have actually done myself.

That said, one should of course also be humble and recognize that one’s own experience is only directly relevant in few cases, and of course we engage experts and other stakeholders in all cases, but it is nevertheless a different perspective one gets from having started and run companies.

The scientific background, and ability to grasp and challenge scientific backgrounds of projects and companies, is essential for an investor in the life science space, and indeed I believe most of my peers in other venture funds have scientific and/or clinical backgrounds.

Read More

John Boghossian

Can you share the inspiration and vision behind founding Kadence Bio?
The inspiration for Kadence Bio stemmed from our founders’ early investigations into potential acute treatments for mood disorders, where they explored different classes of alkaloid small molecules. We discovered a compound scaffold with a distinctive pharmacokinetic profile that also exhibited an unexpected effect of delayed ejaculation. This – rather unexpected! – The finding was corroborated by the elucidation of its potential mechanism of action. 
We then identified a significant unmet need, as no FDA-approved treatments exist for premature ejaculation, a condition that affects at least 1 in 20 men and their partners globally and hinders intimacy and well-being in these relationships. We quickly decided to found Kadence Bio, with a vision of cultivating sexual and mental well-being by developing novel treatments for sexual health and mood disorder applications.

Read More

Sharon Cunningham

You are a chartered accountant turned biotech Founder-CEO. Can you share your journey with us? 
After graduating with a Bachelor of Science in Finance, I trained to become a Chartered Accountant with PwC. I later secured a role as a Management Accountant with pharmaceutical company, EirGen Pharma, progressed to Financial Controller and then Head of Finance. During my time there, I obtained my executive MBA. In 2018 I co-founded Shorla Oncology, a specialty pharmaceutical company developing and commercializing innovative oncology drugs addressing unmet needs. I come from an entrepreneurial family and I always knew I would run my own business eventually but I wanted to spend time in practice and industry and gain as much formal education as possible in order to maximise my knowledge and skills, build an industry network and ultimately enhance my credibility in order to ensure success. 

Read More